Innate Immunity in Gastrointestinal Disorders: Basic and Therapeutic Concepts

February 8 – 9, 2012
The Westin Grand Hotel
Munich, Germany

Program

Falk Symposium

CME credits
Awarded with
12
CME credits
12 credit hours (CME) have been awarded for the Falk Symposium 181 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology (EBG).
Preface

Knowledge in gastroenterology and hepatology is dramatically increasing and at the same time, both disciplines are drifting apart even though many open and arising questions would demand a very close interaction. The innate immune system has gained a lot of attention over the last years as we have learned that it lies at the basis of many diseases, with ever new and important players being identified. Furthermore, the recently begun revelation of the enormously complex microbiome, probably a key driving force of our immune system, has generated even more interest in this field. Therefore, the topic “Innate Immunity in gastrointestinal disorders” is perfectly suitable to bring together gastroenterologists, hepatologists and basic scientists to discuss new developments and to generate new concepts.

Faced with these issues, the Scientific Committee of the Falk symposium No. 181 had the pleasure to recruit an exceptional faculty from all over the world reflecting the very best clinicians and researchers in their respective fields. The main focus of the symposium is to highlight the role of the innate immune system in gut and liver disease. A special emphasis will be based on the importance of the gut microbiota, genes and confounding factors in intestinal inflammation and also in liver diseases. Other topics will concentrate on the role of metabolic inflammation, especially in the context of fatty liver diseases. A clinical update will focus on current and future treatment modalities of inflammatory bowel diseases. One might hope that with a closer interaction between gastroenterologists, hepatologists and basic scientists effective therapies in either discipline might be more easily and rapidly translated into clinical practice in the near future.

We are grateful to Ursula Falk and the Falk Foundation, Freiburk, for their generous support and for the perfect organisation of this exciting meeting.

Herbert Tilg for the Scientific Organizing Committee
Innate Immunity in Gastrointestinal Disorders: Basic and Therapeutic Concepts

The Westin Grand Hotel
Munich, Germany

Registration:
Tuesday, February 7, 2012
16.00 – 21.00 h
at the congress office

Scientific Organization:
R. S. Blumberg, Boston (USA)
S. Endres, Munich (Germany)
A. Kaser, Cambridge (Great Britain)
M. P. Manns, Hannover (Germany)
H. Tilg, Hall/Tirol (Austria)

Information:
Prof. Dr. Herbert Tilg
Landeskrankenhaus
Hall i.T.
Interne Abteilung
Milserstr. 10
6060 Hall / Tirol
Austria
Telephone: +43(0)50/5043 61 45
Telefax: +43(0)50/5043 61 47
E-mail: herbert.tilg@i-med.ac.at

Official Language:
English

Posters:
For details see page 10
**Wednesday, February 8, 2012**

**Liver disease and innate immunity – Basic and therapeutic concepts**

**Session I**

**Autoimmune liver disease and PBC: From animal models to innovative therapies**

**Chair:** T. H. Karlsen, Oslo; M. P. Manns, Hanover

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.30</td>
<td>The liver as an immune organ</td>
<td>P. A. Knolle</td>
<td>Bonn</td>
</tr>
<tr>
<td>9.00</td>
<td>Animal models for autoimmune liver disease – what is relevant</td>
<td>E. Jäckel</td>
<td>Hanover</td>
</tr>
<tr>
<td></td>
<td>for immune mediated liver disease?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.30</td>
<td>Autoimmune hepatitis – New guidelines, new therapies</td>
<td>C. P. Strassburg</td>
<td>Hanover</td>
</tr>
<tr>
<td>10.00</td>
<td>What’s new in primary biliary cirrhosis?</td>
<td>M. E. Gershwin</td>
<td>Davis</td>
</tr>
<tr>
<td>10.30</td>
<td><strong>Coffee break with poster session</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Session II**

**Innate immunity: Key role in liver disorders**

**Chair:** A. L. Gerbes, Munich; M. E. Gershwin, Davis

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.00</td>
<td>Genetics and the aetiopathogenesis of primary sclerosing cholangitis</td>
<td>T. H. Karlsen</td>
<td>Oslo</td>
</tr>
<tr>
<td>11.30</td>
<td>Primary sclerosing cholangitis – New approaches to diagnosis,</td>
<td>M. Trauner</td>
<td>Vienna</td>
</tr>
<tr>
<td></td>
<td>surveillance and treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00</td>
<td>Role of pro-inflammatory cytokines in liver injury</td>
<td>C. Trautwein</td>
<td>Aachen</td>
</tr>
<tr>
<td>12.30</td>
<td>Innate immunity in hepatitis C: Role in disease susceptibility and</td>
<td>H. Wedemeyer</td>
<td>Hanover</td>
</tr>
<tr>
<td></td>
<td>therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00</td>
<td><strong>Lunch break with poster session</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Wednesday, February 8, 2012

#### Session III
**Fatty liver diseases: Innate immunity as driving force for metabolic inflammation?**

**Chair:** R. M. Schmid; Munich; H. Tilg, Innsbruck

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00</td>
<td>The intestinal microbiota: A key player in obesity and related disorders?</td>
<td>F. Bäckhed</td>
<td>Gothenburg</td>
</tr>
<tr>
<td>14.30</td>
<td>ER stress, chronic inflammation and metabolic disease</td>
<td>G. S. Hotamisligil</td>
<td>Boston</td>
</tr>
<tr>
<td>15.00</td>
<td>Innate immunity in NAFLD</td>
<td>A. M. Diehl</td>
<td>Durham</td>
</tr>
<tr>
<td>15.30</td>
<td>Innate immunity and alcoholic liver disease</td>
<td>G. Szabo</td>
<td>Worcester</td>
</tr>
<tr>
<td>16.00</td>
<td><strong>Coffee break with poster session</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Session IV
**Fatty liver diseases: Histopathology and treatment**

**Chair:** B. Göke, Munich

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.30</td>
<td>NAFLD: What the pathologist can tell the clinician</td>
<td>E. M. Brunt</td>
<td>St. Louis</td>
</tr>
<tr>
<td>17.00</td>
<td>NASH – Clinical spectrum and therapy of NASH</td>
<td>C. P. Day</td>
<td>Newcastle</td>
</tr>
<tr>
<td>17.30</td>
<td><strong>State-of-the-Art Lecture I</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TLR’s in GI-diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.00</td>
<td><strong>End of afternoon session</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Thursday, February 9, 2012

Intestinal diseases and innate immunity

Session V
The new world of IBD: About genes, bacteria and viruses

Chair: R. S. Blumberg, Boston; A. Kaser, Cambridge

8.30 High throughput human gut metagenomics study
J. Wang, Shenzhen

9.00 The genetics universe of Crohn’s disease and ulcerative colitis
M. Parkes, Cambridge

9.30 Colitis: Host-microbial detrimentalism?
W. Garrett, Boston

10.00 Could IBD be an infection in a genetically susceptible host?
T. S. Stappenbeck, St. Louis

10.30 Coffee break with poster session

Session VI
Focus on innate immunity in IBD

Chair: S. Endres, Munich; S. Schreiber, Kiel

11.00 New players in the intestinal innate immune system
J. Ruland, Munich

11.30 The inflamasome in inflammatory bowel disease (IBD)
M. Schnurr, Munich

12.00 Animal models of IBD
M. F. Neurath, Erlangen

12.30 Inflammation and colorectal cancer
F. R. Greten, Munich

13.00 Lunch break with poster session
Thursday, February 9, 2012

Session VII
Treatment update of IBD
Chair: S. Brand, Munich; B. Siegmund, Berlin

14.10  5-ASA: Novel aspects of an old drug  A. Dignass, Frankfurt
14.40  A diminishing role of steroids in IBD?  T. Ochsenkühn, Munich
15.10  Thiopurines and biologicals: Where do they fit in?  J.-F. Colombel, Lille
15.40  Predicting the course of IBD: Light at the end of the tunnel?  J. Lee, Cambridge
16.10  Coffee break with poster session

Session VIII
The future of IBD: Genetics meets Therapeutics
Chair: T. Ochsenkühn, Munich; H. Tilg, Innsbruck

16.40  New IBD therapies on the horizon  P. Rutgeerts, Leuven
17.10  How genetics insights may will transform clinical medicine  S. Schreiber, Kiel
17.40  State-of-the-Art Lecture II
       Interleukin-1ß and the treatment of auto-inflammatory diseases  C. A. Dinarello, Aurora
18.10  End of meeting
Poster Session

Posters will be exhibited on February 8–9, 2012, at the Westin Grand Hotel in Munich. The authors will be in attendance during coffee and lunch breaks on both days.

1. Endoplasmic reticulum stress-induced enteritis in XBP1-deficient mice is dependent on NFκB signaling
   (Cambridge, GB; Feldkirch, Innsbruck, Hall/Tirol, AT; Boston, US)

2. Endoplasmic reticulum stress-induced enteritis in XBP1-deficient mice is dependent on TNF receptor signaling
   (Cambridge, GB; Feldkirch, Innsbruck, Hall/Tirol, AT; Boston, US)

3. Analysis of STAT3c-mediated chronic colitis
   I. Backert, M.F. Neurath, K. Floh, C. Becker, C. Neufert (Erlangen, DE)

4. Lack of Atg7 affects Paneth cell granule formation but does not compromise immune homeostasis in the gut
   C. Becker, C. Günther, E. Martini, M. Waldner, M.F. Neurath, N. Wittkopf
   (Erlangen, DE)

5. Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with inflammatory bowel disease

   M.F. Dawwas, G.P. Aithal (Nottingham, GB)

7. Dendritic cell subsets and serum interleukin-12 in schistosomal hepatic fibrosis: Relation to severity of liver disease and renal injury

8. Peripheral blood and intrahepatic natural killer cells and activated hepatic stellate cells in chronic hepatitis C: Relation to disease activity and hepatic fibrosis
   (Alexandria, EG)
9. Effects of budesonide-UDCA combined therapy on histological evolution of primary biliary cirrhosis
   A. Genunche-Dumitrescu, P. Mitrut, M. Badea, D. Badea, A. Badea (Craiova, RO)

10. Budesonide versus prednisone in treatment of autoimmune hepatitis
    A. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut, A. Badea (Craiova, RO)

11. Th2 associated transcription factor NFATc3 protects mice in experimental colitis-model
    K. Gerlach, M.F. Neurath, B. Weigmann (Erlangen, DE)

12. Giardiasis in irritable bowel syndrome suspected patients – An underestimated disease in adults?
    E. Gologan, S. Manea, G. Stefanescu, D. Achitei, G. Balan (Iasi, RO)

13. Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis
    C. Günther, E. Martini, N. Wittkopf, K. Amann, B. Weigmann, H. Neumann, M.J. Waldner, S.M. Hedrick, S. Tenzer, M.F. Neurath, C. Becker (Erlangen, Mainz, DE; San Diego, USA)

14. A polymorphism in melanoma differentiation-associated gene 5 is associated with spontaneous clearance of hepatitis C virus

15. COX-2 immunoexpression in ulcerative colitis and ulcerative colitis-associated neoplasia
    T. Ilias, O. Fratila, D. Puscasiu, C. Banciu (Oradea, Timisoara, RO)

16. Assessment of inflammatory response in patients with alcoholic liver disease
    B. Kasztelan-Szczerbinska, A. Surdacka, M. Slomka, J. Rolinski, K. Celinski, M. Szczerbinski (Lublin, PL)

17. Gender affects immune response in patients with alcoholic liver disease
    B. Kasztelan-Szczerbinska, A. Surdacka, M. Slomka, J. Rolinski, K. Celinski, M. Szczerbinski (Lublin, PL)

18. A novel genetic variant within PNPLA3-SREBP1c pathway represents a general risk factor for hepatic fibrosis: Elastography-based study in patients with chronic liver diseases
    M. Krawczyk, F. Grünhage, M. Mahler, F. Lammert (Homburg, DE)
19. Biliary anti-neutrophil cytoplasmic antibodies are associated with disease severity in primary sclerosing cholangitis  
H. Lenzen, T.J. Weismüller, A.A. Negm, M.P. Manns, T.O. Lankisch (Hannover, DE)

20. Relationship between plasma concentrations of fibronectin and endotoxin antibodies in chronic hepatitis (CH) and liver cirrhosis (LC)  
B.N. Levitan, G. Levitan (Astrakhan, RU)

21. Inflammatory responses of the intestinal epithelium  
E. Martini, C. Günther, N. Wittkopf, M.F. Neurath, C. Becker (Erlangen, DE)

22. Interleukin-33/ST2 signalling in the pathogenesis of liver fibrosis  
T. Mchedlidze, S. Pflanz, M. Schuchmann, M. Vieth, M.F. Neurath, S. Wirtz (Erlangen, Mainz, Bayreuth, DE; Foster City, US)

23. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders  

24. Intra- and extracellular pre-B cell colony-enhancing factor modulates hepatic inflammation in experimental hepatitis  

25. Chronic pancreatitis with autoimmune origin in children  
G. Oracz, B. Cukrowska, J. Kierkus, M. Dadalski, J. Ryzko, J. Socha (Warsaw, PL)

26. Immunogenetic features of HCV-related fatigue  
A.O. Romanov, T.V. Belyaeva (St. Petersburg, RU)

27. Expression of hepcidin and heme oxygenase-1 in chronic hepatitis  
K. Sikorska, T. Romanowski, P. Stalke, K.P. Bielawski (Gdansk, PL)

28. The role of Kupffer cells in the pathogenesis of non-alcoholic steatohepatitis: Immunohistochemical and ultrastructural findings in pediatric patients  
M.E. Sobaniec-Lotowska, J.M. Lotowska, S.B. Bockowska, D.M. Lebensztejn (Bialystok, PL)

29. Correlation of hepatic steatosis with iron overload in chronic hepatitis C  
P. Stalke, K. Sikorska, T. Romanowski, R. Rzepko, K.P. Bielawski (Gdansk, PL)
30. Interplay between systemic markers of inflammation and kidney function in patients with alcoholic liver disease
   M. Szczерbinski, B. Kasztelan-Szczersinska, A. Surdacka, M. Slomka, J. Rolinski, K. Celinski (Lublin, PL)

31. Increased apoptosis of regulatory T cells in patients with chronic inflammatory bowel disease

32. Secondary sclerosing cholangitis in critically ill patients: Clinical presentation and prognostic factors for fatal outcome

33. Analysing the role of mucosal mast cells inducing colitis-associated colorectal cancer
   B. Weigmann, M. Stassen, C. Taube, M.F. Neurath (Erlangen, Mainz, DE)

34. Interferon-\(\alpha\) signalling drives pathogenic immune responses during microbiota induced septic peritonitis
   S. Wirtz, T. Mchedlidze, L. Shen, M.F. Neurath (Erlangen, DE)

35. Intestinal epithelial Stat3 activation controls C. rodentium infection
   N. Wittkopf, U. Billmeier, C. Günther, E. Martini, S. Wirtz, M.F. Neurath, C. Becker (Erlangen, DE)

36. Interrelation between the functional state of erythrocytes and morphological parameters in children with inflammatory bowel disease
   A.B. Yazykova, P.P. Potekhin, L.V. Korkotashvili, S.A. Kolesov, E.N. Fedulova, O.V. Fedorova (Nizhny Novgorod, RU)

37. The role of capsule endoscopy in evaluating and managing small bowel disorders
   E. Yoong, K. Padmakumar (Manchester, Bolton, GB)
List of Speakers, Moderators and Scientific Organizers

Dr. Fredrik Bäckhed
University of Göteborg
Sahlgrenska Sjukhuset
Wallenberg Laboratory
413 45 Göteborg
Sweden
fredrik.backhed@wlab.gu.se

Richard S. Blumberg, M.D.
Professor of Medicine
Harvard Medical School
Brigham and Women’s Hospital
GI Division
75 Francis Street
Boston MA 02115
USA
rblumberg@partners.org

Prof. Dr. Stephan Brand
Medizinische Klinik II
Klinikum der Universität
München - Großhadern
Marchioninistr. 15
81377 München
Germany
stephan.brand@med.uni-muenchen.de

Elizabeth M. Brunt, M.D.
Professor of Pathology
Washington University
School of Medicine
Pathology & Immunology
660 S. Euclid Avenue
St. Louis MO 63110
USA
ebrunt@wustl.edu

Prof. Dr. Jean-Frederic Colombel
Hôpital Claude Huriez
CHRU Lille
Gastroenterology & Hepatology
1, Place de Verdun
59037 Lille
France
jfcolombel@chru-lille.fr

Prof. Dr. Christopher P. Day
University of Newcastle
The Medical School
Center for Liver Research
William Leech Building
Framlington Place
Newcastle-Upon-Tyne NE2 4HH
Great Britain
c.p.day@ncl.ac.uk

Anna Mae Diehl, M.D.
Professor of Medicine
Duke University Medical Center
Gastroenterology Division
Box 3256, Snyderman/GSRB-1
595 LaSalle Street
Durham NC 27710
USA
annamae.diehl@duke.edu

Prof. Dr. Axel Dignass
Innere Medizin I
Agaplesion
Markus Krankenhaus
Wilhelm-Epstein-Str. 4
60431 Frankfurt
Germany
axel.dignass@fdk.info

Charles A. Dinarello, M.D.
Professor of Medicine
University of Colorado Denver
12700 East 19th Ave., B168
Aurora CO 80045
USA
cdinare333@aol.com

Prof. Dr. Stefan Endres
Klinische Pharmakologie
Klinikum der Universität
München - Innenstadt
Ziemssenstr. 1
80336 München
Germany
stefan.endres@med.uni-muenchen.de
Wendy Garrett, M.D., Ph.D.
Assistant Professor of Immunology
Harvard School of Public Health
Department of Immunology & Infectious Diseases
665 Huntington Ave.
Boston MA 02115
USA
wgarrett@hsp.harvard.edu

Gökhan S. Hotamisligil, M.D., Ph.D.
Professor of Genetics
Harvard School of Public Health
Genetics & Complex Diseases
665 Huntington Ave.
Boston MA 02115
USA
ghotamis@hsph.harvard.edu

Prof. Dr. Alexander L. Gerbes
Medizinische Klinik II
Klinikum der Universität München - Großhadern
Marchioninistr. 15
81377 München
Germany
gerbes@med.uni-muenchen.de

Dr. Elmar Jäckel
Klinik für Gastroenterologie, Hepatologie und Endokrinologie
Medizinische Hochschule Hannover
Carl-Neuberg-Str. 1
30625 Hannover
Germany
jaeckel.elmar@mh-hannover.de

M. Eric Gershwin, M.D.
Professor of Medicine
University of California
School of Medicine
Rheumatology & Allergy
One Shields Ave., Tupper Hall
Davis CA 95616
USA
megershwin@ucdavis.edu

Dr. Tom Hemming Karlsen
Norwegian PSC Research Center
Medical Department
Oslo University Hospital
Rikshospitalet
0027 Oslo
Norway
tomhk@ulrik.uio.no

Prof. Dr. Burkhard Göke
Medizinische Klinik II
Klinikum der Universität München - Großhadern
Marchioninistr. 15
81377 München
Germany
burkhard.goike@med.uni-muenchen.de

Prof. Dr. Florian R. Greten
Innere Medizin II
Klinikum rechts der Isar der Technischen Universität
Ismaninger Str. 22
81675 München
Germany
florian.grethen@lrz.tum.de

Prof. Dr. Arthur Kaser
University of Cambridge
Addenbrooke’s Hospital
Division of Gastroenterology & Hepatology
Hills Road
Cambridge CB2 0QQ
Great Britain
ak729@cam.ac.uk

Prof. Dr. Percy A. Knolle
Molekulare Medizin
Universitätsklinikum Bonn
Sigmund-Freud-Str. 25
53127 Bonn
Germany
percy.knolle@ukb.uni-bonn.de
Dr. James Lee  
University of Cambridge  
Addenbrooke’s Hospital  
Box 139  
Hills Road  
Cambridge CB2 0QQ  
Great Britain  
drjameslee@gmail.com

Prof. Dr. Michael P. Manns  
Klinik für Gastroenterologie, Hepatologie und Endokrinologie  
Medizinische Hochschule Hannover  
Carl-Neuberg-Str. 1  
30625 Hannover  
Germany  
manns.michael@mh-hannover.de

Prof. Dr. Markus F. Neurath  
Medizinische Klinik 1  
Universitätsklinikum Erlangen  
Ulmenweg 18  
91054 Erlangen  
Germany  
markus.neurath@uk-erlangen.de

PD Dr. Thomas Ochsenkühn  
Medizinische Klinik II  
Klinikum der Universität München - Großhadern  
Marchioninstr. 15  
81377 München  
Germany  
thomas.ochsenkuehn@med.uni-muenchen.de

Dr. Miles Parkes  
University of Cambridge  
Addenbrooke’s Hospital  
Gastroenterology Unit  
Hills Road  
Cambridge CB2 0QQ  
Great Britain  
miles.parkes@addenbrookes.nhs.uk

Prof. Dr. Jürgen Ruland  
Klinische Chemie/Pathobiochemie  
Klinikum rechts der Isar der Technischen Universität  
Ismaninger Str. 22  
81675 München  
Germany  
jruland@lrz.tu-muenchen.de

Prof. Dr. Paul Rutgeerts  
University Ziekenhuis Gasthuisberg  
Gastro-enterologie  
Herestraat 49  
3000 Leuven  
Belgium  
paul.rutgeerts@uz.kuleuven.ac.be

Prof. Dr. Roland M. Schmid  
Innere Medizin II  
Klinikum rechts der Isar der Technischen Universität  
Ismaninger Str. 22  
81675 München  
Germany  
roland.schmid@lrz.tum.de

PD Dr. Maximilian Schnurr  
Innere Medizin  
Klinikum der Universität München - Innenstadt  
Ziemssenstr. 1  
80336 München  
Germany  
max.schnurr@med.uni-muenchen.de

Prof. Dr. Stefan Schreiber  
Innere Medizin I  
Universitätsklinikum Schleswig-Holstein, Campus Kiel  
Arnold-Heller-Straße 3 (Haus 6)  
24105 Kiel  
Germany  
s.schreiber@mucosa.de

16
PD Dr. Britta Siegmund  
Gastroenterologie  
Charité Universitätsmedizin  
Campus Benjamin Franklin (CBF)  
Hindenburgdamm 30  
12203 Berlin  
Germany  
britta.siegmund@charite.de

Thaddeus S. Stappenbeck, M.D., Ph.D.  
Associate Professor of Pathology & Immunology  
Washington University  
School of Medicine  
Division of Biology & Biomedical Sciences  
1020 Clinical Science Res. Bldg.  
St. Louis MO 63110  
USA  
stappenb@wustl.edu

Prof. Dr. Christian P. Strassburg  
Klinik für Gastroenterologie, Hepatologie und Endokrinologie  
Medizinische Hochschule Hannover  
Carl-Neuberg-Str. 1  
30625 Hannover  
Germany  
strassburg.christian@mh-hannover.de

Prof. Dr. Michael Trauner  
Medizinische Universität Wien  
Klinische Abteilung für Gastroenterologie & Hepatologie  
Währinger Gürtel 18-20  
1090 Wien  
Austria  
michael.trauner@meduniwien.ac.at

Prof. Dr. Christian Trautwein  
Medizinische Klinik III  
Universitätsklinikum Aachen  
Pauwelsstr. 30  
52074 Aachen  
Germany  
ctrautwein@ukaachen.de

Prof. Dr. H. Wagner  
Mikrobiologie und Hygiene  
Technische Universität München  
Trogerstr. 9  
81675 München  
Germany  
h.wagner@lrz.tum.de

Prof. Dr. Jun Wang  
BGI  
Yantian District  
Beishan Industrial Zone  
518083 Shenzhen  
P. R. China  
wangj@genomics.org.cn

Prof. Dr. Heiner Wedemeyer  
Klinik für Gastroenterologie, Hepatologie und Endokrinologie  
Medizinische Hochschule Hannover  
Carl-Neuberg-Str. 1  
30625 Hannover  
Germany  
wedemeyer.heiner@mh-hannover.de

Prof. Dr. Herbert Tilg  
Landeskrankenhaus  
Hall i.T.  
Interne Abt.  
Milserstr. 10  
6060 Hall / Tirol  
Austria  
herbert.tilg@i-med.ac.at

Gyongyi Szabo, M.D., Ph.D.  
Professor of Medicine  
University of Massachusetts  
Medical School  
Department of Medicine  
55 Lake Avenue North  
Worcester MA 01655  
USA  
gyongyi.szabo@umassmed.edu

Prof. Dr. Herbert Tilg  
Landeskrankenhaus  
Hall i.T.  
Interne Abt.  
Milserstr. 10  
6060 Hall / Tirol  
Austria  
herbert.tilg@i-med.ac.at
Congress Office

During the V Falk Gastro-Conference

The Westin Grand Hotel Arabellastr. 6
81925 Munich
Germany

Telephone: +49 (0) 175 / 77 95 327
Telefax: +49 (0) 89 / 92 64 92 01

Opening Hours:
- Tuesday, February 7, 2012 16.00 – 21.00 h
- Wednesday, February 8, 2012 7.30 – 18.00 h
- Thursday, February 9, 2012 8.00 – 18.10 h
- Friday, February 10, 2012 8.00 – 18.15 h
- Saturday, February 11, 2012 8.00 – 18.10 h

Congress Fees

Scientific program of the Falk Symposium 181
- Students and residents
  - € 200,-
  - € 100,-

* * * OR * * *

Day ticket
- Students and residents
  - € 120,-
  - € 60,-

The congress fees include:
- Welcome Evening on February 7, 2012
- Refreshments during coffee breaks
- Lunch on February 8 and 9, 2012
- A copy of the abstract volume

Admission to Scientific Events

For admission to scientific events your name badge should be clearly visible.

Congress Report

The official congress report of the Falk Symposium 181 “Innate Immunity in Gastro-intestinal Disorders: Basic and Therapeutic Concepts” will be published in English in the second half of 2012 by Karger Publishers, Basel, Switzerland. Orders for this book at a reduced subscription price of € 35,- can be placed at the Congress Office during the congress in Munich.

Congress Short Report

The congress short report of the V Falk Gastro-Conference will be published by the Falk Foundation e.V. with number FSK 181-182 in the second half on 2012. Orders for this short report, free of charge, can be placed with the Falk Foundation e.V.
Innovative Drugs
for bowel and liver diseases
Modern formulations and specially designed delivery systems ensure targeted release of the active drug

Scientific Dialogue
in the interest of therapeutic progress
Falk Symposia and Workshops
nearly 250, attended by more than 100,000 participants from over 100 countries since 1967
Continuing medical education seminars
over 14,000, attended by more than one million physicians and patients in Germany alone
Comprehensive literature service for healthcare professionals and patients
with more than 200 publications